Notable 52-Week Highs and Lows 11/29: (ARIA) (TIF) (THO) High; (NVLS) (FCEL) Low

November 29, 2016 3:43 PM EST

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

52-Week High:
  • ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) $14.42. ARIAD Pharma announced that the U.S. Food and Drug Administration (FDA) has granted Iclusig (ponatinib) full approval for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) for whom no other tyrosine kinase inhibitor (TKI) therapy is indicated; and for the treatment of adult patients with T315I-positive CML (chronic phase, accelerated phase, or blast phase) or T315I positive Ph+ ALL.

  • Tiffany & Co. (NYSE: TIF) $84.39. Tiffany & Co. reported Q3 EPS of $0.76, which was $0.08 better than the analyst estimate of $0.68. Revenue for the quarter came in at $949.3 million versus the consensus estimate of $922.6 million. Constant currency comps fell 3 percent, versus a drop of 4.1 percent expected by analysts.

  • Thor Industries (NYSE: THO) $104.38. Thor Industries reported Q1 EPS of $1.49, versus the analyst estimate of $1.23. Revenue for the quarter came in at $1.71 billion versus the consensus estimate of $1.5 billion.

  • Booz Allen Hamilton (NYSE: BAH) $38.54. Booz Allen Hamilton announced that it has entered into an agreement to acquire the Laurel, MD-based digital services firm eGov Holdings, Inc. (d/b/a Aquilent), a premiere architect of .gov solutions for the Federal government, for whom it deploys cutting-edge digital, agile, DevOps, and cloud capabilities. Booz Allen has agreed to pay a purchase price of $250 million in connection with the transaction, subject to customary purchase price adjustments and customary escrows.
52-Week Low:
  • Nivalis Therapeutics, Inc. (Nasdaq: NVLS) $2.50. Nivalis Therapeutics announced topline results from the Company's Phase 2 trial evaluating the efficacy and safety of two doses of cavosonstat, 200 mg and 400 mg, in adult patients with CF who had two copies of the F508del-CFTR mutation and were being treated with Orkambi. There were no dose limiting toxicities and cavosonstat was well tolerated at all doses in the trial. The trial failed, however, to demonstrate benefit in absolute change in percent predicted FEV1, the trial’s primary endpoint, or in sweat chloride reduction at 12 weeks.

  • FuelCell Energy (Nasdaq: FCEL) $2.02. FuelCell Energy lower as FBR Capital cut its price target on the stock from $5.50 down to $3. For more color, click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Special Reports

Related Entities

Definitive Agreement

Add Your Comment